Literature DB >> 21470373

Correlation of assessment of plasma cells by flow cytometry and detection of cytogenomic abnormalities by fluorescence in situ hybridization in plasma cell neoplasms.

G Lu1, X X Zhang, M J You, W Chen.   

Abstract

INTRODUCTION: Increased monoclonal plasma cell count (PCC) in bone marrow (BM) is an indicator of a plasma cell neoplasm (PCN). Assessing PCC in BM by morphologic evaluation (ME) and flow cytometry (FC) is important in diagnosing PCN. Also important is fluorescence in situ hybridization (FISH) to detect cytogenomic abnormalities (CAs) in PCN. Owing to FC's short turnaround time, FC-assessed PCC is often used as empirical reference for further FISH study. However, correlation of FC-assessed PCs with FISH-detected CAs has not been well studied. The purpose of this study was to validate this correlation on BM aspirates from patients with PCN.
METHODS: We reviewed 224 cases of newly diagnosed PCN identified from our Lab-database. Both FC and FISH had been performed on BM aspirates from these cases, of which 178 had been assessed by ME. The original findings from the 224 cases were also reviewed.
RESULTS: Using a cut-off of 3% PCs assessed by FC as an indicator for further FISH analysis, 20 (17%) FISH-detectable PCN cases were missed; 30% of the missed cases carried high-risk CAs and/or were highly progressive PCN.
CONCLUSION: In PCN cases, an FC-assessed 3% PCC in BM aspirates should not be used as a cut-off for further FISH testing.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 21470373     DOI: 10.1111/j.1751-553X.2011.01323.x

Source DB:  PubMed          Journal:  Int J Lab Hematol        ISSN: 1751-5521            Impact factor:   2.877


  1 in total

1.  Plasma cell enrichment enhances detection of high-risk cytogenomic abnormalities by fluorescence in situ hybridization and improves risk stratification of patients with plasma cell neoplasms.

Authors:  Gary Lu; Ramya Muddasani; Robert Z Orlowski; Lynne V Abruzzo; Muzaffar H Qazilbash; M James You; Yaping Wang; Ming Zhao; Su Chen; Isabella Claudia Glitza; L Jeffrey Medeiros
Journal:  Arch Pathol Lab Med       Date:  2013-05       Impact factor: 5.534

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.